The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis
View/ Open
Author
Freedberg, Kenneth A
Possas, Cristina
Deeks, Steven
Ross, Anna Laura
Rosettie, Katherine L
Di Mascio, Michele
Collins, Chris
Walensky, Rochelle P
Yazdanpanah, Yazdan
Metadata
Show full item recordCitation
Freedberg, Kenneth A, Cristina Possas, Steven Deeks, Anna Laura Ross, Katherine L Rosettie, Michele Di Mascio, Chris Collins, Rochelle P Walensky, and Yazdan Yazdanpanah. 2015. “The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis.” Journal of Virus Eradication 1 (4): 245-249.Abstract
Abstract The research agenda towards an HIV cure is building rapidly. In this article, we discuss the reasons for and methodological approach to using mathematical modelling and cost-effectiveness analysis in this agenda. We provide a brief description of the proof of concept for cure and the current directions of cure research. We then review the types of clinical economic evaluations, including cost analysis, cost-benefit analysis and cost-effectiveness analysis. We describe the use of mathematical modelling and cost-effectiveness analysis early in the HIV epidemic as well as in the era of combination antiretroviral therapy. We then highlight the novel methodology of Value of Information (VOI) analysis and its potential role in the planning of clinical trials. We close with recommendations for modelling and cost-effectiveness analysis in the HIV cure agenda.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748959/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002509
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)